One of the clearest long-term risks of second-generation antipsychotic treatment is metabolic — weight gain, insulin resistance, and in some cases new-onset type 2 diabetes. The risk is real but predictable, and predictable problems are catchable problems. Routine glucose and A1c monitoring is the backbone of that safety net.
The 2004 ADA/APA consensus and subsequent guidelines recommend a fasting glucose or A1c at baseline, 3 months, and then annually for everyone on antipsychotics, with closer monitoring for higher-risk drugs and patients.
Why this matters
Antipsychotic-associated weight gain and insulin resistance can lead to type 2 diabetes within months, not years. People with schizophrenia already have roughly two to three times the diabetes risk of the general population, before any medication is added. Olanzapine, clozapine, and to a slightly lesser extent quetiapine and risperidone, raise this risk further. The result is that cardiovascular disease — much of it driven by diabetes — accounts for most of the 15- to 20-year shortened life expectancy seen in schizophrenia. Catching glucose changes early reverses that arc.
The ADA/APA consensus monitoring schedule
The 2004 American Diabetes Association / American Psychiatric Association Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes set the standard schedule, which is still widely used:
- Baseline — personal and family history, weight (BMI), waist circumference, blood pressure, fasting plasma glucose, fasting lipid panel.
- 4 weeks — weight.
- 8 weeks — weight.
- 12 weeks — weight, blood pressure, fasting glucose, fasting lipids.
- Quarterly — weight.
- Annually — blood pressure, fasting glucose, fasting lipids.
- Every 5 years — fasting lipid panel if previously normal (in low-risk patients only; most modern guidelines recommend annual).
Many clinicians now substitute HbA1c for fasting glucose because it does not require fasting, reflects average blood sugar over 2–3 months, and aligns with current diabetes diagnosis criteria.
What the numbers mean
Diabetes diagnostic thresholds (per ADA):
- Normal: fasting glucose < 100 mg/dL, A1c < 5.7%
- Prediabetes: fasting glucose 100–125 mg/dL, A1c 5.7–6.4%
- Diabetes: fasting glucose ≥ 126 mg/dL on two occasions, A1c ≥ 6.5%, or random glucose ≥ 200 with symptoms
Which antipsychotics carry the most risk
- Highest: olanzapine, clozapine
- Moderate: quetiapine, risperidone, paliperidone
- Lower: aripiprazole, brexpiprazole, lurasidone, ziprasidone, lumateperone, cariprazine, asenapine
Lower-risk does not mean no risk. Annual monitoring is recommended for all antipsychotics, including the so-called weight-neutral agents.
What to do if your glucose or A1c rises
- Lifestyle first — every modern guideline puts diet, physical activity, and weight management at the centre. See exercise vs antipsychotic weight gain.
- Consider a switch — moving from olanzapine or clozapine to a more weight-neutral agent can stop or reverse the trend. This is a clinical decision that has to weigh how well the current medication is working.
- Add metformin — strong evidence supports metformin for weight gain and insulin resistance on antipsychotics, even in patients without overt diabetes. See metformin for antipsychotic weight gain.
- Treat the diabetes — if you cross into diabetes, you need diabetes care. That can include metformin, GLP-1 agonists, or other agents. Glucose lowering reduces cardiovascular and overall mortality.
You develop frequent urination, extreme thirst, blurred vision, unexplained weight loss, fruity breath, nausea, or confusion — these can be signs of diabetic ketoacidosis (DKA), which has been reported especially with olanzapine, sometimes very early in treatment.
The DKA warning
The FDA labels for olanzapine and several other atypicals carry warnings about hyperglycemia and DKA, which has occurred in some patients within weeks of starting treatment, sometimes even without major weight gain. Anyone starting these medications should know the symptoms above and have a low threshold for getting checked.
Practical questions to ask your prescriber
- What is my baseline A1c?
- How often will we check it?
- What number would prompt a treatment change?
- Is metformin appropriate for me?
- If we switch antipsychotics, what is the next best option?
The big picture
Glucose monitoring is one of the most important pieces of antipsychotic care, and one of the most often neglected. The labs are cheap, the diagnostic criteria are clear, and effective interventions exist at every stage. Asking for the test is one of the strongest things a patient can do for their own long-term health.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.